Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Siegfried Holding AG ( (CH:SFZN) ) is now available.
DINAMIQS, a Siegfried company, has inaugurated Switzerland’s first cGMP manufacturing facility for viral vectors, enhancing its capabilities in the cell and gene therapy market. This facility, located in Zurich, integrates R&D, clinical, and commercial manufacturing, and is set to strengthen Siegfried’s market position. DINAMIQS has also announced a strategic collaboration with SEAL Therapeutics to develop a gene therapy for muscular dystrophy, showcasing its commitment to advancing innovative treatments.
The most recent analyst rating on (CH:SFZN) stock is a Buy with a CHF119.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.
More about Siegfried Holding AG
The Siegfried Group is a global life sciences company with operations in Switzerland, Germany, Spain, France, Malta, the USA, and China. In 2024, the company reported sales of CHF 1.295 billion and employed over 3,800 people across thirteen sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange and is involved in manufacturing pharmaceutical APIs, drug products, and providing development services.
YTD Price Performance: -20.35%
Average Trading Volume: 61,924
Technical Sentiment Signal: Sell
Current Market Cap: CHF3.53B
For a thorough assessment of SFZN stock, go to TipRanks’ Stock Analysis page.